Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 11/20 | 0.54 |
| ▸ | F3 | P13726 | 11/20 | 0.54 |
| ▸ | F10 | P00742 | 10/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 10/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 10/20 | 0.54 |
| ▸ | F2 | P00734 | 8/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.45 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GCK | P35557 | 1/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.38 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5883243 | 1.00 | F7 (0.54) | F7F3F10PRSS1PRSS2 | |
| SCHEMBL5883364 | 0.99 | F7 (0.55) | F7F3F10PRSS1PRSS2 | |
| SCHEMBL5883369 | 0.99 | F7 (0.55) | F7F3F10PRSS1PRSS2 | |
| SCHEMBL5882287 | 0.95 | F7 (0.57) | F7F3F10PRSS1PRSS2 | |
| SCHEMBL5882285 | 0.95 | F7 (0.57) | F7F3F10PRSS1PRSS2 | |
| SCHEMBL5882558 | 0.92 | F7 (0.52) | F7F3F10PRSS1PRSS2 | |
| SCHEMBL5882557 | 0.92 | F7 (0.52) | F7F3F10PRSS1PRSS2 | |
| SCHEMBL5882556 | 0.89 | F10 (0.66) | F7F3F10PRSS1PRSS2 | |
| SCHEMBL5882435 | 0.87 | F7 (0.56) | F7F3F10PRSS1PRSS2 | |
| SCHEMBL5883044 | 0.85 | F7 (0.56) | F7F3F10PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6476264-B2 | ANTICOAGULANT | HOFFMANN-LA ROCHE INC. | 2002-11-05 | — | — | US | disclosed |
| US-6242644-B1 | FOR TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION, INFLAMATION AND ARTHEROSCLEROSIS | HOFFMANN-LA ROCHE INC. | 2001-06-05 | — | — | US | disclosed |
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | ACKERMANN JEAN (CH) | 2001-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010001799-A1 | N-(4- carbamimidoyl-phenyl) -glycine derivatives | GLRA1, NGLY1, GLS | F7 1019/4885F3 2017/4885F10 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.